Exhibitors Search
ATEMs
Booth no.
A62
|
Exhibition
|
|NextRegenX |
|---|---|
|
Country
|
| Korea, South |
|
Address
|
|7 Jeongui-ro 8-gil, Songpa-gu, Seoul, Republic of Korea |
|
Tel
|
|+82-024017943-- |
|
Exhibits
|
| A-Paste-C, CartiSave |
|
Company Type
|
| Pharmaceutical / Drug Development Company , Biotech Venture / Startup , Regenerative Medicine Company , Digital Health / Medical Device Company |
Exhibitor Information
* Mission: ATEMs Provides Human with the Joy of Activity
* Platform: Focusing on Degenerative and Intractable Diseases using AMC and CAM/SAM Platforms
- Grade-Specific Treatment Strategy: Provide Total Solutions for All Grades of Osteoarthritis
- AMC(ATEMs Medicinal cell)
- CAM(Cartilage Acellular Matrix)
- SAM(Skin Acellular Matrix)
* History
- Series A investment(19.08)
- Establishment of GMP facilities(20.05)
- IND Approval for Phase I clinical trial of A-Paste-C(23.08)
- CartiSave is approved as a Medical Device(24.02)
- ISO 13485 Certification(25.06)
- Approval for Cell Processing Facility(25.08)
- Approval for Management Business of Human Cells and Tissues(25.10)
- IND Approval for Phase I of A-Paste-D(25.10)
- Phase 1 Patient Enrollment Completed of A-Paste-C(25.12)
- Cartisave nHTA Clinical Patient Registration Completed(25.06)
- Phase 1 Clinical Trial Initiation of A-Paste-D(26.08)
* Platform: Focusing on Degenerative and Intractable Diseases using AMC and CAM/SAM Platforms
- Grade-Specific Treatment Strategy: Provide Total Solutions for All Grades of Osteoarthritis
- AMC(ATEMs Medicinal cell)
- CAM(Cartilage Acellular Matrix)
- SAM(Skin Acellular Matrix)
* History
- Series A investment(19.08)
- Establishment of GMP facilities(20.05)
- IND Approval for Phase I clinical trial of A-Paste-C(23.08)
- CartiSave is approved as a Medical Device(24.02)
- ISO 13485 Certification(25.06)
- Approval for Cell Processing Facility(25.08)
- Approval for Management Business of Human Cells and Tissues(25.10)
- IND Approval for Phase I of A-Paste-D(25.10)
- Phase 1 Patient Enrollment Completed of A-Paste-C(25.12)
- Cartisave nHTA Clinical Patient Registration Completed(25.06)
- Phase 1 Clinical Trial Initiation of A-Paste-D(26.08)
Exhibit Description
* AMC(ATEMs Medicinal cell)
- Scaffold-free 3D cartilage: Fetal chondrocytes+Self-produced ECM
- Injectable, Single-step procedure: Applicable to various sizes and shapes
- Off-the-shelf: Long-term storage (2 years,< -150 ℃)
- 1 Donor tissue → more than 500,000 treatments
- Expansion of Target Indications: A-Paste-D(Degenerative Disc Disease, DDD), A-Paste-GP(Growth Plate Injury)
* CAM(Cartilage Acellular Matrix)&SAM(Skin Acellular Matrix)
- ATEM’s Decellularization Technique
- Advanced Raw Material Processing Technology: such as gel, solution, film, sponge
- No immune response
- Provides a Natural Tissue Environment
- Scaffold-free 3D cartilage: Fetal chondrocytes+Self-produced ECM
- Injectable, Single-step procedure: Applicable to various sizes and shapes
- Off-the-shelf: Long-term storage (2 years,< -150 ℃)
- 1 Donor tissue → more than 500,000 treatments
- Expansion of Target Indications: A-Paste-D(Degenerative Disc Disease, DDD), A-Paste-GP(Growth Plate Injury)
* CAM(Cartilage Acellular Matrix)&SAM(Skin Acellular Matrix)
- ATEM’s Decellularization Technique
- Advanced Raw Material Processing Technology: such as gel, solution, film, sponge
- No immune response
- Provides a Natural Tissue Environment
Individual Exhibit/Technology Introduction (Detailed)
-
Product Name : A-Paste-C* The New Standard Cartilage Regeneration "A-Paste-C (ICRS 3~4)" * Phase 1 Clinical Trial ( n=7) -VAS:Reduced by 70% at Week 24 - KOOS:Improved by 40% at Week 48 -MOCRT:Average score ≥ 65 at Weeks 48 * Dstinctive Features - Scaffold-free 3D cartilage:Fetal chondrocytes+Self-produced ECM - Injectable, Single-step procedure:Applicable to various sizes and shapes - Off-the-shelf:Long-term storage (2 years,< -150 ℃) - 1 Donor tissue → more than 500,000 treatments - MoA: Fundamental Treatment via Defect Regeneration * Expansion of Target Indications - A-Paste-D(Degenerative Disc Disease, DDD):Phase 1 Clinical Trial(26.3Q~) - A-Paste-GP(Growth Plate Injury):Clinical trials being prepared under regenerative medicine regulations
-
Product Name : CartiSave* The only Intra-articular Collagen Injection"CartiSave (KL Grade 1~3) " * Clinical Trial - Superior efficacy over the control group (HA) at 24 weeks * Distinctive Features - Class IV Medical Device - The cartilage-derived ECM containing collagen type II and proteoglycan - Provides a Natural Cartilage Environment - MoA: Providing a growth environment for chondrocytes via supplementation of cartilage ECM
KYUNGYON EXHIBITION CORP.
